{
    "Clinical Trial ID": "NCT00382018",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Arm C1 (Baseline CTCs >= 5, Day 22 CTCs >= 5, High Risk)",
        "  Patients had increased CTCs at baseline (defined as five or more CTCs per 7.5 mL WB) and >= 5 CTCs at first follow-up (Day 22). Patients would be randomized to maintain current therapy.",
        "INTERVENTION 2: ",
        "  Arm C2 (Baseline CTCs >= 5, Day 22 CTCs >= 5, High Risk)",
        "  Patients had increased CTCs at baseline (defined as five or more CTCs per 7.5mL WB) and >= 5CTCs at first follow-up (Day22). Patients would be randomized to change therapy to a different drug or combination of drugs."
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Histologically confirmed breast cancer",
        "  Clinical evidence of metastatic disease (stage IV disease)",
        "  Newly metastatic disease OR progressive metastatic disease while on hormonal therapy",
        "  Meets 1 of the following criteria:",
        "  Measurable disease",
        "  Bone-only disease* NOTE: *Patients with nonmeasurable disease that does not include bone are not eligible",
        "  HER-2 status determined by immunohistochemistry (IHC) or fluorescent in situ hybridization (FISH) assay",
        "  HER-2 positivity is defined as IHC 3+ or FISH+",
        "  If IHC is indeterminate (2+), FISH must be performed to classify disease",
        "  Planning to undergo first-line chemotherapy for metastatic disease",
        "  Patients with brain metastases must have stable disease for > 90 days after completion of prior radiotherapy to the brain",
        "  No leptomeningeal disease",
        "  Hormone receptor status not specified",
        "  PATIENT CHARACTERISTICS:",
        "  Female",
        "  Menopausal status not specified",
        "  Zubrod performance status 0-2",
        "  Not pregnant or nursing",
        "  Negative pregnancy test",
        "  No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or stage I or II cancer currently in complete remission",
        "  PRIOR CONCURRENT THERAPY:",
        "  See Disease Characteristics",
        "  Prior hormonal therapy, bisphosphonate therapy, trastuzumab (Herceptin\u00ae), and/or bevacizumab for metastatic disease allowed",
        "  Any number of exogenous hormonal therapies for metastatic disease and/or as adjuvant therapy allowed",
        "  At least 1 year since prior adjuvant chemotherapy",
        "  At least 2 weeks since prior minor surgery and recovered",
        "  At least 4 weeks since prior major surgery and recovered",
        "  No prior chemotherapy for metastatic disease",
        "  Concurrent hormonal therapy and/or bisphosphonate therapy allowed",
        "  Concurrent trastuzumab and/or bevacizumab allowed"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Overall Survival",
        "  From date of registration to date of death due to any cause. Patients last known to be alive are censored at date of last contact.",
        "  Time frame: Every 3 months until progression then every 6 months for 5 years or until death",
        "Results 1: ",
        "  Arm/Group Title: Arm C1 (Baseline CTCs >= 5, Day 22 CTCs >= 5, High Risk)",
        "  Arm/Group Description: Patients had increased CTCs at baseline (defined as five or more CTCs per 7.5 mL WB) and >= 5 CTCs at first follow-up (Day 22). Patients would be randomized to maintain current therapy.",
        "  Overall Number of Participants Analyzed: 64",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: months  10.7        (9.1 to 14.8)",
        "Results 2: ",
        "  Arm/Group Title: Arm C2 (Baseline CTCs >= 5, Day 22 CTCs >= 5, High Risk)",
        "  Arm/Group Description: Patients had increased CTCs at baseline (defined as five or more CTCs per 7.5mL WB) and >= 5CTCs at first follow-up (Day22). Patients would be randomized to change therapy to a different drug or combination of drugs.",
        "  Overall Number of Participants Analyzed: 59",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: months  12.5        (8.4 to 16.3)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/161 (0.00%)",
        "  Gastrointestinal-Other 0/161 (0.00%)",
        "  Dehydration 0/161 (0.00%)",
        "  Renal/Genitourinary-Other 0/161 (0.00%)",
        "Adverse Events 2:",
        "  Total: 1/64 (1.56%)",
        "  Gastrointestinal-Other 1/64 (1.56%)",
        "  Dehydration 1/64 (1.56%)",
        "  Renal/Genitourinary-Other 1/64 (1.56%)"
    ]
}